Immunosurveillance, Immunodeficiencies and Lymphoproliferations: Lymphoproliferative Disorders in Congenital and Acquired Immunodeficiencies

Front Matter....Pages I-X
Immunosurveillance, Immunodeficiency and Lymphoproliferations....Pages 1-8
Clinicopathologic Characteristics of Post-Transplant Lymphoproliferative Disorders....Pages 9-18
Iatrogenic Lymphoproliferative Disorders in Non-Transplantation Settings....Pages 19-26
The Role of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV/HHV-8) in Lymphoproliferative Diseases....Pages 27-37
Dendritic Cells for the Induction of EBV Immunity....Pages 38-43
NF-κB Inhibition in EBV-Transformed Lymphoblastoid Cell Lines....Pages 44-48
Epstein-Barr Viral Load as a Tool to Diagnose and Monitor Post-Transplant Lymphoproliferative Disease....Pages 49-54
The Role of Immunosuppression in Lymphoma....Pages 55-66
Identification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders....Pages 67-80
Methods and Objectives of a Large US Multicenter Case-Control Study of Post-Transplant Lymphoproliferative Disorder in Renal Transplant Patients....Pages 81-88
Antiviral Treatment of Epstein-Barr Virus-Associated Lymphoproliferations....Pages 89-95
Low-Dose Chemotherapy for Children with Post-Transplant Lymphoproliferative Disease....Pages 96-103
Engineered Antibody for Treating Lymphoma....Pages 104-112
Treatment of Post-Transplant Lymphomas with Anti-B-Cell Monoclonal Antibodies....Pages 113-122
Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas....Pages 123-133
Non-Myeloablative Stem Cell Transplantation for Congenital Immunodeficiencies....Pages 134-142
Prognostic Factors in the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma....Pages 143-148
Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma: Preliminary Results of a Phase I/II Study....Pages 149-153
Back Matter....Pages 155-158